首頁 > 市場調查報告書 > 醫療設備

生技設備

生物銀行市場規模、佔有率和成長分析（按產品和服務、生物樣本庫類型、樣本類型、儲存方法、所有權、應用、最終用戶和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898697

生物銀行市場規模、佔有率和成長分析（按產品和服務、生物樣本庫類型、樣本類型、儲存方法、所有權、應用、最終用戶和地區分類）—產業預測（2026-2033 年）

Biobanking Market Size, Share, and Growth Analysis, By Product &Service (Equipment, Consumables), By Biobanks Type, By Sample Type, By Storage Type, By Ownership, By Application, By End user, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，生物銀行市場規模將達到 769 億美元，到 2025 年將達到 821.2 億美元，到 2033 年將達到 1390.1 億美元，在預測期（2026-2033 年）內，複合年成長率為 6.8%。

在技術創新、數據分析和自動化的推動下，生物銀行產業正經歷顯著的擴張。這項發展催生了虛擬生物樣本庫的出現，不僅提高了傳統生物樣本庫的運作效率，也釋放了巨大的市場潛力。包括疾病相關生物樣本庫、人源生物樣本庫、組織樣本庫和血庫在內的各類生物樣本庫，構成了一個多元化的市場格局，並受益於退化性疾病的日益增加。最尖端科技的整合加速了研究方法的改進，最大限度地縮短了處理時間，提高了生物樣本庫的收入，最終提升了整體市場價值。此外，旨在最佳化生物銀行營運和促進虛擬系統應用的軟體開發投入不斷增加，也推動了生物銀行市場的強勁成長。

生物銀行市場促進因素

生物銀行市場的主要驅動力是基因組研究的拓展和個人化醫療的進步。人們對遺傳標記與疾病進展之間關聯的理解不斷加深，促使生物樣本庫需要儲存高品質的生物樣本用於基因組分析。這些生物樣本在幫助研究人員開發標靶治療發揮關鍵作用，使生物樣本庫處於新興醫療創新領域的前沿。對生物銀行日益成長的依賴性表明，它在促進個人化治療方法的突破和改善整體醫療保健效果方面至關重要。

生物銀行市場的限制

生物銀行市場面臨許多限制因素，其中涉及生物樣本的採集、儲存和使用方面的倫理和法律問題。對病患隱私、知情同意以及敏感資料潛在濫用的擔憂，為生物樣本庫的建立和運作帶來了巨大挑戰。這些問題削弱了公眾的信任和接受度，使得生物樣本庫難以在現有的監管框架下有效運作。如何在嚴格遵守倫理標準與確保透明度和保密性之間取得平衡，仍然是一個重大障礙，影響著生物銀行業務的整體成長和永續性。

生物銀行市場趨勢

生物銀行市場正經歷一個顯著的趨勢：人工智慧 (AI) 與巨量資料分析的融合。這種技術融合能夠實現更精準的檢體追蹤、最佳化資料管理並提升檢體保存品質。 AI 驅動的分析使研究人員能夠從海量生物樣本資料集中發現模式並獲得洞見，從而幫助識別新的生物標記並加速藥物研發舉措。透過利用這些先進技術，生物樣本庫不僅提高了營運效率，還為個人化醫療和創新療法的突破性進展做出了貢獻，使其成為生物醫學研究領域的核心參與者。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Thermo Fisher Scientific Inc.（United States）
Merck KGaA（Germany）
QIAGEN NV（Netherlands）
Hamilton Company（United States）
Tecan Trading AG（Switzerland）
Becton, Dickinson and Company（BD）（United States）
Lonza Group AG（Switzerland）
Charles River Laboratories International, Inc.（United States）
BioLife Solutions, Inc.（United States）
Brooks Automation, Inc.（United States）
Greiner Bio-One International GmbH（Austria）
STEMCELL Technologies Inc.（Canada）
Chart Industries, Inc.（United States）
BioIVT（United States）
Firalis SA（France）
Celltex Therapeutics Corporation（United States）
Sigma-Aldrich Corporation（United States）
Hope Biosciences（United States）
54Gene（Nigeria）

結論與建議

簡介目錄

Product Code: SQMIG35H2200

Biobanking Market size was valued at USD 76.9 Billion in 2024 and is poised to grow from USD 82.12 Billion in 2025 to USD 139.01 Billion by 2033, growing at a CAGR of 6.8% during the forecast period (2026-2033).

The biobanking sector is experiencing significant expansion, fueled by technological advancements, data analytics, and automation. This evolution has led to the emergence of virtual biobanks, which enhance the operational efficiency of traditional biobanks, unlocking substantial market potential. Various types of biobanks, including disease-related, human-based, tissue, and blood banks, contribute to a diverse landscape, particularly benefiting from the increasing prevalence of degenerative diseases. The integration of cutting-edge technologies accelerates the research process, minimizes processing times, and enhances revenue generation for biobanks, subsequently elevating the overall market value. Furthermore, software development initiatives are on the rise, aimed at optimizing biobanking operations and promoting the adoption of virtual systems, which collectively drive robust growth within the biobanking market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biobanking market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biobanking Market Segments Analysis

Global Biobanking Market is segmented by Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user and region. Based on Product &Service, the market is segmented into Equipment, Consumables, Services and Software. Based on Biobanks Type, the market is segmented into Physical/Real Biobanks, Tissue Biobanks, Population Based Biobanks, Genetic (DNA/RNA), Disease Based Biobanks and Virtual Biobanks. Based on Sample Type, the market is segmented into Blood Products, Human Tissues, Cell Lines, Nucleic Acids, Biological Fluids and Human Waste Products. Based on Storage Type, the market is segmented into Manual Storage and Automated Storage. Based on Ownership, the market is segmented into Universities, National/Regional Agencies, Non-Profit Organizations and Private Organizations. Based on Application, the market is segmented into Regenerative Medicine, Life Science Research and Clinical Research. Based on End user, the market is segmented into Pharmaceutical, Biotechnology Companies and CROs, Academic, Research Institutes and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biobanking Market

A significant catalyst for the biobanking market is the expanding landscape of genomics research and the advancement of personalized medicine. With increased comprehension of genetic markers and their relation to disease progression, there is a heightened need for biobanks that preserve high-quality biosamples for genomic analysis. These biosamples play a critical role in enabling researchers to develop targeted therapies, thereby positioning biobanks at the forefront of emerging healthcare innovations. This growing reliance on biobanking underscores its vital importance in facilitating breakthroughs in personalized treatment approaches and enhancing overall healthcare outcomes.

Restraints in the Biobanking Market

In the biobanking market, significant constraints arise from the ethical and legal considerations associated with the collection, storage, and utilization of biospecimens. Concerns regarding patient privacy, informed consent, and potential misuse of sensitive data pose considerable challenges to the establishment and operation of biobanks. These issues can hinder public trust and acceptance, making it difficult for biobanks to function effectively within the existing regulatory landscape. The need to balance stringent compliance with ethical standards while ensuring transparency and confidentiality remains a critical obstacle, impacting the overall growth and sustainability of biobanking initiatives.

Market Trends of the Biobanking Market

The biobanking market is witnessing a significant trend characterized by the integration of artificial intelligence (AI) and big data analytics. This technological fusion enhances specimen tracking, optimizes data management, and elevates the quality of specimen storage. AI-driven analytics empower researchers to uncover patterns and derive insights from extensive biosample datasets, thereby facilitating the identification of new biomarkers and expediting drug development initiatives. As biobanks harness these advanced technologies, they not only improve operational efficiencies but also contribute to groundbreaking advancements in personalized medicine and innovative therapeutic solutions, positioning themselves as pivotal players in the biomedical research landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Biobanking Market Size by Product &Service & CAGR (2026-2033)

Market Overview
Equipment
- Storage Equipment
- Sample Analysis Equipment
- Sample Processing Equipment
- Sample Transport Equipment
Consumables
- Storage Consumables
- Analysis Consumables
- Processing Consumables
- Collection Consumables
Services
- Storage Services
- Processing Services
- Transport Services
- Supply Services
Software

Global Biobanking Market Size by Biobanks Type & CAGR (2026-2033)

Market Overview
Physical/Real Biobanks
Tissue Biobanks
Population Based Biobanks
Genetic (DNA/RNA)
Disease Based Biobanks
Virtual Biobanks

Global Biobanking Market Size by Sample Type & CAGR (2026-2033)

Market Overview
Blood Products
Human Tissues
Cell Lines
Nucleic Acids
Biological Fluids
Human Waste Products

Global Biobanking Market Size by Storage Type & CAGR (2026-2033)

Market Overview
Manual Storage
Automated Storage

Global Biobanking Market Size by Ownership & CAGR (2026-2033)

Market Overview
Universities
National/Regional Agencies
Non-Profit Organizations
Private Organizations

Global Biobanking Market Size by Application & CAGR (2026-2033)

Market Overview
Regenerative Medicine
Life Science Research
Clinical Research

Global Biobanking Market Size by End user & CAGR (2026-2033)

Market Overview
Pharmaceutical
Biotechnology Companies and CROs
Academic
Research Institutes
Hospitals

Global Biobanking Market Size & CAGR (2026-2033)

North America (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
- US
- Canada
Europe (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
- Brazil
- Rest of Latin America
Middle East & Africa (Product &Service, Biobanks Type, Sample Type, Storage Type, Ownership, Application, End user)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hamilton Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tecan Trading AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories International, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioLife Solutions, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Brooks Automation, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Greiner Bio-One International GmbH (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
STEMCELL Technologies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chart Industries, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioIVT (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Firalis S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celltex Therapeutics Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sigma-Aldrich Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hope Biosciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
54Gene (Nigeria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments